Acorn Capital Advisors’s Cardiff Oncology CRDF Stock Holding History

Acorn Capital Advisors’s Portfolio CRDF Stock Details CRDF Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.85M	Sell	1,762,084 -200,000	-10%	-$411K	0.81%	16
2025 Q4	$5.51M	Hold	1,962,084	–	–	1.87%	12
2025 Q3	$4.04M	Buy	1,962,084 +553,317	+39%	+$1.53M	2.05%	12
2025 Q2	$4.44M	Sell	1,408,767 -33,541	-2%	-$102K	2.9%	12
2025 Q1	$4.53M	Hold	1,442,308	–	–	3.02%	13
2024 Q4	$6.26M	Buy	+1,442,308	New	+$4.51M	3.37%	12

Other funds holding CRDF

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

LCM

Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return

Pfizer New York $239M AUM 232.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return

FLPIM

F.L. Putnam Investment Management Lynnfield, Massachusetts $6.71B AUM 23.99% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Acorn Capital Advisors's CRDF Position: Q1 2026 in Review

Acorn Capital Advisors reduced its Cardiff Oncology (CRDF) stake by 10% in Q1 2026, selling an estimated $411K and leaving 1,762,084 shares worth $2.85M. The position accounts for 0.81% of the portfolio, ranked #16.

Acorn Capital Advisors first reported a position in CRDF in Q4 2024 and has held it in 6 quarters since. The position peaked at $6.26M in Q4 2024. 116 funds tracked by Wall St. Rank hold CRDF as of Q1 2026.

Acorn Capital Advisors held 1,762,084 shares of Cardiff Oncology worth $2.85M as of Q1 2026.
Acorn Capital Advisors sold 200,000 Cardiff Oncology shares in Q1 2026, an estimated $411K.
Cardiff Oncology made up 0.81% of Acorn Capital Advisors's portfolio in Q1 2026, its #16 holding.
Acorn Capital Advisors first reported a position in Cardiff Oncology in Q4 2024 and has held it in 6 quarters since.
Acorn Capital Advisors's Cardiff Oncology position peaked at $6.26M in Q4 2024.
116 funds tracked by Wall St. Rank held Cardiff Oncology as of Q1 2026.

Based on Acorn Capital Advisors's 13F filing for Q1 2026, filed 15 May 2026.